Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Cost of Product Revenues: $811M in FY2025, up 20.6% from a year earlier. That is the highest of the 9 years on record here.
Latest, FY2025
811
Period ended Dec 31, 2025
Change on a year earlier
+20.6%
672 in FY2024
History
9 years
Since FY2017
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (2026-02-27) ↗
Reported in Form 10-K/10-Q (DB).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of Product Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 811 | +20.6% | Form 10-K (2026-02-27) ↗ |
| FY2024 | Dec 31, 2024 | 672 | +14.2% | Form 10-K (2025-02-28) ↗ |
| FY2023 | Dec 31, 2023 | 589 | +29.8% | Form 10-K (2024-02-29) ↗ |
| FY2022 | Dec 31, 2022 | 454 | +43.9% | Form 10-K (2023-03-01) ↗ |
| FY2021 | Dec 31, 2021 | 315 | +57.5% | Form 10-K (2023-03-01) ↗ |
| FY2020 | Dec 31, 2020 | 200 | +23.1% | Form 10-K (2023-03-01) ↗ |
| FY2019 | Dec 31, 2019 | 163 | +2.8% | Form 10-K (2020-03-02) ↗ |
| FY2018 | Dec 31, 2018 | 158 | +16.7% | Form 10-K (2020-03-02) ↗ |
| FY2017 | Dec 31, 2017 | 136 | – | Form 10-K (2020-03-02) ↗ |
Cite this data
StockData. (2026). Natera Cost of Product Revenues ($M), annual FY2017–FY2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/db-seg-product-cor
See every metric in the Natera KPI table. Data updated Nov 2, 2026.